Azitra Unveils Positive Preclinical Results for ATR-01 in Ichthyosis Vulgaris
I'm PortAI, I can summarize articles.
Azitra, Inc. has announced positive preclinical results for its ATR-01 program, aimed at treating ichthyosis vulgaris. The engineered strain ATR01-616 secretes functional human filaggrin protein, demonstrating effectiveness in reducing transepidermal water loss and repairing damaged skin in preclinical tests. Detailed findings will be presented at the BIO-Europe® conference in Vienna from November 3-5, 2025. Updates on clinical programs ATR-12 and ATR-04 were also provided, with more information on ATR-01's path to first-in-human studies expected in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments